U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054320) titled 'Rapamycin and Infection-related Illness' on June 27.
Brief Summary: Conduct a 6-month observational pilot clinical trial to evaluate the safety, monitor the adverse reactions and observe the preliminary effectiveness of medical treatment with oral rapamycin [Rapamune (Sirolimus)] in a total of 15 adults, 18 years and older toward preventing and lowering the severity of infectious disease or infection-related illness.
Rapamune (Sirolimus) is not approved by the United States Food and Drug Administration (FDA) to prevent and lessen the severity of infection-related illness or infectious disease. Rapamune (Sirolimus) is approved by the...